一区二区三区在线视频观看I久久亚洲色图I日韩av免费I国产乱码精品一区二区三区精东I久久久久久久伊人I美女张开腿露出尿口I91亚洲国产成人久久精品网站I日韩精品成人在线观看Iwww.狠狠撸.comI精精国产I国产成人在线看I韩国中文字幕hd久久精品I国产又黄又刺激的视频I最大av在线I综合一区I国产精品久久久久蜜臀Iwww.youjizz日本I男人的天堂国产Iav永久免费I99国产精品99久久久久久粉嫩I亚洲草逼视频I成人精品水蜜桃I色噜噜噜I成年精品I特级全黄久久久久久久久I国产激情视频在线观看I亚洲精品久久久久久无码色欲四季

冬凌草甲素

分析標準品,HPLC≥98%

Oridonin

CAS號：28957-04-2

分子式：C20H28O6

分子量：364.43

MDL：MFCD00221762

產品介紹

Oridonin是從Rabdosia rubescens中得到的二萜，是一種AKT抑制劑，對 AKT1 和 AKT2 的IC50值分別為 8.4 和 8.9 μM，具有抗菌、抗炎、抗腫瘤等功效。

熔點：248-250℃

沸點：599.8℃ at 760 mmHg

比旋光度：(c, 0.1 in EtOH)-47

外觀：淡黃色針狀結晶

溶解性：DMSO:62.5mg/mL(171.50mM;Needultrasonic)

儲存條件：2-8℃

注意：部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。

參考文獻(46篇)

46. [IF=6.8] Kong Jiahui et al."Biomimetic MOFs Nanoparticles Co-Delivering Oridonin and siRNA for Synergistic Therapy in Melanoma via ferroptosis pathway."Journal of Science-Advanced Materials and Devices.2025 Jul;:100957

45. [IF=5.4] Junli Zhang et al."Screening Isodon rubescens-Derived Vesicles Harvested at Different Periods as Carriers for the Treatment of Colitis-Associated Cancer."ACS Biomaterials Science & Engineering.2025;XXXX(XXX):XXX-XXX

44. [IF=3] Jushuang Li et al."Oridonin ameliorates renal fibrosis in diabetic nephropathy by inhibiting the Wnt/β-catenin signaling pathway."RENAL FAILURE.

43. [IF=6] Mengting Li et al."Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury."EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.2024 Aug;:116760

42. [IF=1.8] Gengzhen Huang et al."Oridonin attenuates diabetes?induced renal fibrosis via the inhibition of TXNIP/NLRP3 and NF?κB pathways by activating PPARγ in rats."EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES".2024 May;0:

41. [IF=14.5] Mengru Cai et al."An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy."Acta Pharmaceutica Sinica B".2024 May;:

40. [IF=4.6] Tianming Lu et al."Inhibition of ALDOA and ENO1-mediated Glycolysis of Oridonin as a Novel Anti-tumor Strategy of Non-small Cell Lung Cancer."Advanced Therapeutics".2024 Apr;:2400027

39. [IF=5] Shiying Ye et al."Oridonin promotes RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress signaling pathway JNK/Nrf2/HO-1."EUROPEAN JOURNAL OF PHARMACOLOGY".2024 Apr;:176620

38. [IF=3.8] Zhang Feifan et al."Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells."BMC CANCER".2024 Dec;24(1):1-11

37. [IF=4.5] Lunji Wang et al."Antibacterial Mechanisms and Antivirulence Activities of Oridonin against Pathogenic Aeromonas hydrophila AS 1.1801."Microorganisms".2024 Feb;12(2):415

36. [IF=9.965] Mengru Cai et al."Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin."JOURNAL OF COLLOID AND INTERFACE SCIENCE.2023 Apr;:

35. [IF=2.602] ZHOU Wei et al."Preparation and characterization of an oridonin and γ-cyclodextrin complex."Food Science and Technology.2022 Aug;42:

34. [IF=5.811]

33. [IF=2.248] Yang Huiyu et al."Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells."Anti-Cancer Drug. 2022 Jan;33(1):e444-e452

32. [IF=2.447] Yun Gui et al."Oridonin improves the therapeutic effect of lentinan on lung cancer."Exp Ther Med. 2021 Aug;22(2):1-9

31. [IF=3] Qu  Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950

30. [IF=3.361] Mengru Cai et al."Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior."Rsc Adv. 2020 Oct;10(60):36862-36872

29. [IF=3.503] Lili  Tian et al."Preliminary safety assessment of oridonin in zebrafish."Pharm Biol. 2019;57(1):632-640

28. [IF=3.591] Mengru Cai et al."Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers."New J Chem. 2020 Oct;44(41):17693-17704

27. [IF=6.543] Hong Mu-keng et al."Oridonin Alters Hepatic Urea Cycle via Gut Microbiota and Protects against Acetaminophen-Induced Liver Injury."Oxid Med Cell Longev. 2021;2021:3259238

26. [IF=0] Gan Zhao et al."Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury."Oncotarget. 2017 Sep 15; 8(40): 68153–68164

25. [IF=1.785] Tao  Xu et al."Oridonin enhances in vitro anticancer effects of lentinan in SMMC?7721 human hepatoma cells through apoptotic genes."Exp Ther Med. 2017 Nov;14(5):5129-5134

24. [IF=2.833] Tian  Lili et al."Antiangiogenic effects of oridonin."Bmc Complem Altern M. 2017 Dec;17(1):1-15

23. [IF=3.361] Jushuang Li et al."Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways."Int Immunopharmacol. 2018 Feb;55:9

22. [IF=3.571] Xiangling  Xiao et al."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways."Int J Oncol. 2016 Jun;48(6):2608-2618

21. [IF=3.723] Yang Sun et al."Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma."Chem-Biol Interact. 2018 Dec;296:57

20. [IF=5.722] Liu  Qian-Qian et al."Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway."Cancer Cell Int. 2016 Dec;16(1):1-8

19. [IF=5.959] Lu  Ying et al."Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway."Cell Death Dis. 2018 Jan;9(1):1-16

18.  Tian, L., Xie, K., Sheng, D. et al. Antiangiogenic effects of oridonin. BMC Complement Altern Med 17, 192 (2017). https:##doi.org/10.1186/s12906-017-1706-3

17.  Zhao G, Zhang T, Ma X, et al. Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury. Oncotarget. 2017;8(40):68153-68164. Published 2017 Jul 12. doi:10.18632/oncotarget.19249

16.  Xiao, X., He, Z., Cao, W., Cai, F., Zhang, L., Huang, Q., Fan, C., Duan, C., Wang, X., Wang, J., Liu, Y."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways". International Journal of Onco

15.  Yang Sun, Xiubo Jiang, Ying Lu, Jianwei Zhu, Lisha Yu, Bo Ma, Qi Zhang, Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma, Chemico-Biological Interactions,

14.  Jushuang Li, Liping Bao, Dongqing Zha, Lian Zhang, Ping Gao, Juan Zhang, Xiaoyan Wu, Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways, International Immunopharmaco

13.  Cai, Mengru, et al. "Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers." New Journal of Chemistry 44.41 (2020): 17693-17704.DOI https:##doi.org/10.1039/D0NJ03680C

12.  王倩,糾敏,孟媛媛,孔銘杰,殷成芮,汪倫記.冬凌草甲素/殼聚糖復合膜對冰鮮雞胸肉的保鮮效果[J].食品與機械,2021,37(03):125-130.

11.  李崢, 王強, 張曉莉. 藍萼香茶菜提取溶劑的選擇及其耐缺氧作用研究[J]. 中華中醫藥學刊, 2012, 030(006):1375-1377.

10.  何中維 肖香玲 蔡芬 張亮 黃秋月 段超 劉瑩.冬凌草甲素逆轉人胃癌細胞SGC 7901/DDP順鉑耐藥的作用及機制研究[J].湖北醫藥學院學報 2016 35(03):261-265+226.

9.  尚曙玉  張鐵山  郝海軍 等. 冬凌草甲素磷脂復合物不同制劑在SD大鼠體內生物利用度的比較[J]. 中藥材  2019  v.42;No.422(04):170-173.

8.  杜利月  郭留城  郝海軍 等. 冬凌草甲素滲透泵片制備工藝研究及體外評價[J]. 中藥材  2018  v.41；No.407(01):173-176.

7.  田麗莉  盛東來  朱國福. 冬凌草甲素抑制血管生成活性及作用機制[J]. 中國實驗方劑學雜志  2016  022(005):166-171.

6.  糾敏  閆鵬  閆國慶 等. 冬凌草甲素對金黃色#葡萄*球菌的抑菌作用機制[J]. 江蘇農業科學  2019  47(07):202-206.

5.  糾敏  閆鵬  李晶晶 等. 冬凌草甲素對金黃色#葡萄*球菌生物膜的抑制機制[J]. 微生物學通報  2020  v.47(05):250-256.

4.  田麗莉  朱國福  盛東來. 冬凌草甲素對人臍靜脈內皮細胞的抑制作用[J]. 溫州醫學院學報  2017  047(012):880-883 887.

3.  肖香玲 何中維 黃秋月 季娟麗 張云飛 劉瑩.冬凌草甲素下調EGFR/ERK/MMP-12和CIP2A/Akt信號通路抑制gefitinib耐受的非小細胞肺癌的轉移[J].湖北醫藥學院學報 2016 35(06):536-542+629.

2.  糾敏  孟媛媛  王倩 等. 冬凌草甲素/殼聚糖復合膜的性能和結構表征[J]. 食品與發酵工業  2019  045(024):119-123.

1.  汪倫記  許美秋  糾敏 等. 冬凌草提取物對金黃色#葡萄*球菌生物膜形成的抑制作用[J]. 天然產物研究與開發  2017  029(006):1000-1005.

從2011年開始我們致力于在生命科學領域、生物醫學實驗技術及論文潤色服務，協助客戶各類實驗服務及論文潤色十余年，是您值得信賴的科研合作伙伴!

如果您受時間、試驗條件等限制而無法完成您的課題研究，歡迎您與我們聯系。

實驗技術服務：